COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02830165
Recruitment Status : Active, not recruiting
First Posted : July 12, 2016
Last Update Posted : February 28, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Delivering radiotherapy before prostatectomy by SBRT is more convenient, conformal, and may spare normal tissues better than delivering radiotherapy after prostatectomy.

Condition or disease Intervention/treatment Phase
Stage I Prostate Adenocarcinoma Stage II Prostate Adenocarcinoma Stage III Prostate Adenocarcinoma Other: Laboratory Biomarker Analysis Other: Quality-of-Life Assessment Radiation: Stereotactic Body Radiation Therapy Not Applicable

Detailed Description:


I. To assess feasibility of pre-operative stereotactic body radiotherapy (SBRT) in prostate cancer patients at high risk for recurrence after prostatectomy.


I. To assess safety and acute toxicity of SBRT followed by prostatectomy. This will be based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and patient reported quality of life (Expanded Prostate Cancer Index Composite [EPIC] and International Prostate Symptom Score [IPSS] questionnaires).

II. Correlative biomarker and molecular analyses using the primary tumor specimen and serial blood draws before and after treatment.


Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.

After completion of the study treatment, patients are followed up every 3 months for 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Feasibility Trial of Preoperative Adjuvant Stereotactic Body Radiotherapy for Patients at High Risk of Local Failure After Prostatectomy
Actual Study Start Date : March 10, 2016
Estimated Primary Completion Date : March 10, 2021
Estimated Study Completion Date : March 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment (SBRT)
Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
Other: Laboratory Biomarker Analysis
Correlative studies

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Radiation: Stereotactic Body Radiation Therapy
Undergo SBRT
Other Name: SBRT

Primary Outcome Measures :
  1. Treatment Completion Rate of Pre-Operative stereotactic body radiotherapy (SBRT). [ Time Frame: At 4 weeks ]
    A two-sided 90% exact binomial confidence interval will be used to measure the treatment completion rate.

Secondary Outcome Measures :
  1. Changes in quality of life, based on the International Prostate Symptom Score (I-PSS) questionnaire [ Time Frame: Baseline to up to 1 year ]
  2. Correlative biomarker analyses using tissue and serial blood samples [ Time Frame: Baseline and to up to 1 year ]
    Tissue specimens of the primary tumor as well as blood draws before and after treatment will be used to conduct biomarker and molecular analyses relevant to understanding the biology of prostate stereotactic body radiation therapy (SBRT)

  3. Incidence of toxicities, based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4 [ Time Frame: Up to 1 year ]
  4. Changes in quality of life, based on the Expanded Prostate Cancer Index Composite (EPIC) questionnaire [ Time Frame: Baseline to up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
  • Patient desires and is medically fit to undergo prostatectomy
  • Karnofsky performance status (KPS) >= 70
  • Patients on androgen deprivation therapy (ADT) are allowed
  • For confirmation of high risk local failure status, patients will have any one of the following:

    • Computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating seminal vesicle invasion (SVI) or extraprostatic extension (EPE) within 1 year of enrollment into the study
    • Pre-biopsy prostate-specific antigen (PSA) >= 20
    • Gleason score 7-10 (Gleason 7 must be 4+3), presence of any Gleason 5 (even if a tertiary score) as determined at diagnostic biopsy
    • Gleason score 7 and > 50% of biopsy cores positive for prostate cancer
    • Clinical stage >= T3 (staging by imaging acceptable)
  • An image-guided biopsy (via Artemis Ultrasound with MRI co-registration) is encouraged but not required if not performed as standard of care biopsy

Exclusion Criteria:

  • Distant metastases, based upon:

    • CT scan or MRI of the abdomen/pelvis within 120 days prior to registration and
    • Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis prior to registration
  • Patient is unable or unwilling to sign consent
  • Patient is considered low-risk and would not have received adjuvant radiation therapy (RT) outside of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02830165

Layout table for location information
United States, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Nicholas Nickols UCLA / Jonsson Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT02830165    
Other Study ID Numbers: 15-001580
NCI-2016-00188 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
15-001580 ( Other Identifier: UCLA / Jonsson Comprehensive Cancer Center )
P30CA016042 ( U.S. NIH Grant/Contract )
First Posted: July 12, 2016    Key Record Dates
Last Update Posted: February 28, 2020
Last Verified: February 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases